1Assessed with APRI score Demographic and clinical characteristics of 429 patients with genotype 2 or 3 treated for 14 or 24 weeks according to week 4 response.
BackgroundThe role of interleukin 28B (IL-28B) polymorphisms played in hepatitis C virus (HCV) infection has been gradually explicit, especially in HCV genotype 1, 2 and 3. However, no confirmative co
Background/Aims: Triple therapy [adding protease inhibitors to standard of care (SOC)] dramatically increases treatment response in selected patients with hepatitis C virus (HCV). Interleukin 28B (IL2
Virologic response rates (rapid virological response, complete early virological response and sustained virological response) to PEGIFN/RBV by PNPLA3-SNP and IL28B-SNP; reported as number (percentage)
